Shijiazhuang Pharma Reports 41.8% Net Profit Drop in Q1 2026; Hengrui Medicine Announces Positive Phase III Results for Oral GLP-1 Agonist HRS-7535
CSPC
Innovative Drug Research and Development, Manufacturer
Hengrui Pharma
Innovative and High-Quality Pharmaceutical Developer
Human Longevity
Genomics-related Health Intelligence Provider
AusperBio
Biological Vaccine and Nucleic Acid Drug Developer
InnoCare
Innovative Drug Developer
Amino Observer - Original Content by the Innovative Drug Group
Author | Huang Kai
CSPC's performance is sluggish.
On May 27, CSPC released its Q1 2026 financial report. During the reporting period, the company's revenue was RMB 6.465 billion, down 5% year-on-year; net profit stood at RMB 859 million, a decrease of 41.8% year-on-year. Following this announcement, the company's stock price plummeted by 5.38%.
Hengrui Pharma Accelerates R&D.
On May 27, Hengrui Pharma and U.S.-based Kailera Therapeutics (Kailera) jointly announced that the Phase III clinical trial (OUTSTAND-1) of the oral small-molecule GLP-1 receptor agonist HRS-7535 (known as KAI-7535 outside Greater China), conducted among 284 adult subjects with type 2 diabetes in China, has achieved positive topline results.
Over the past day, what other key developments in the domestic and international pharmaceutical markets are worth your attention? Let Amin Jun take you on a deep dive.
/ 01 /
Market Update
1) Insilico Medicine and Human Longevity Announce Collaboration
On May 27, Insilico Medicine announced a collaboration with Human Longevity to jointly develop the industry's first AI foundation model for longevity science.
/ 02 /
Capital Information
1) CSPC's Q1 net profit fell 41.8%
On May 27, CSPC released its first-quarter report for 2026. During the reporting period, the company's revenue was RMB 6.465 billion, down 5% year-on-year; net profit was RMB 859 million, down 41.8% year-on-year.
/ 03 /
Pharmaceutical Updates
1) Hengrui Pharma's Oral Small-Molecule GLP-1 Succeeds in Phase III Clinical Trial
On May 27, Hengrui Pharma and U.S.-based Kailera Therapeutics (Kailera) jointly announced that the Phase III clinical trial (OUTSTAND-1) of the oral small-molecule GLP-1 receptor agonist HRS-7535 (known as KAI-7535 outside Greater China), conducted in 284 adult patients with type 2 diabetes in China, has achieved positive top-line results.
2) AusperBio Announces Phase II Clinical Data for Hepatitis B Oligonucleotide Therapy
On May 27, AusperBio announced that at the 2026 European Association for the Study of the Liver (EASL) Congress, it presented the end-of-follow-up data from its Phase 2 clinical study of AHB-137, an independently developed antisense oligonucleotide (ASO) drug, in treatment-naïve patients with chronic hepatitis B (CHB) (AB-10-8008). The results showed that AHB-137 demonstrated potent and durable antiviral activity in treatment-naïve CHB patients, achieving a functional cure (FC) rate of 70% in the population with baseline HBsAg levels of 100–1000 IU/mL, while the overall safety profile was consistent with expectations.
3) InnoCare's Orelabrutinib Approved for Marketing by Australia's Therapeutic Goods Administration (TGA)
On May 27, InnoCare announced that its independently developed BTK inhibitor orelabrutinib has been approved for marketing by the Australian Therapeutic Goods Administration (TGA) for the treatment of adult patients with relapsed/refractory mantle cell lymphoma (r/rMCL).
4) SanoHubble's SNH-118110 Soft Capsules Receive Clinical Trial Approval
On May 27, according to the official website of the CDE, SinoHubble's SNH-118110 soft capsules received clinical trial approval, intended for the treatment of RET-altered advanced solid tumors.
5）Mingji Biologics' FG-M131 for Injection Receives Clinical Trial Approval
On May 27, according to the official website of the CDE, FG-M131 for injection by Mingji Bio was granted clinical trial approval, intended for previously treated patients with TRBC1-positive relapsed/refractory peripheral T-cell lymphoma.
/ 04 /
Overseas Pharmaceutical News
1) $3.83 Billion, Eli Lilly Acquires Three Anti-Infective Companies
On May 26, Eli Lilly and Company announced the acquisition of three vaccine companies: Curevo Inc. for $1.5 billion, LimmaTech Biologics for $780 million, and Vaccine Company, Inc. for $1.55 billion, to expand its research and development efforts into the field of infectious diseases. These transactions advance Eli Lilly's strategy of investing in differentiated technology platforms to address critical health challenges.
P.S.: Please scan the QR code below to add "Amino Jun" on WeChat for further communication.
